The Safety Advantage of Autologous Therapy: Why Your Own Cells Matter | ALIV

When patients first hear about Autologous Cell Therapy, one of the most reassuring aspects is the word "autologous" itself — the understanding that the biological material used is entirely their own, processed from their own body and returned to their own body. This is not just a marketing claim. The autologous principle has genuine, mechanistically grounded safety implications that distinguish ACT from any therapy involving foreign biological material, donor cells, or manufactured biologics. Understanding both the safety advantages and the actual procedural risks gives patients the complete honest picture they need to make an informed decision.

The Immunological Safety of Autologous Sourcing

The human immune system is exquisitely good at distinguishing self from non-self — a capability developed over millions of years of evolutionary pressure to eliminate pathogens and abnormal cells. The surface markers that allow this distinction (HLA antigens) are unique to each individual. When foreign cells are introduced — in organ transplant, allogeneic blood transfusion, or donor-derived cell therapies — the immune system recognises the non-self HLA signature and mounts an immune response ranging from mild (transfusion reaction) to severe and life-threatening (graft-versus-host disease in bone marrow transplant).

Autologous material — because it carries the patient's own HLA signature — does not trigger this immune recognition. The immune system does not mount a rejection response against its own cells, regardless of how those cells have been processed, concentrated, or administered. This eliminates the entire category of immune rejection risk, the need for immunosuppressive medication before or after the procedure, and the donor-matching requirement that constrains access to allogenic therapies. It also eliminates any risk of transmitting donor-derived infections — a genuine concern with any allogeneic biological material.

What Procedural Risks Actually Exist

Eliminating rejection risk does not mean ACT is without procedural risk — all clinical procedures carry some risk, and honest informed consent requires that patients understand what the actual risks of ACT are. The procedural risks in ALIV's ACT protocols are those of any minimally invasive clinical procedure:

Harvest site risks: Bone marrow harvest from the posterior iliac crest carries a small risk of local infection, bruising, and procedural discomfort that typically resolves over one to two weeks. Adipose harvest (small lipoaspiration) carries similar local procedural risks. These are managed by strict sterile technique, proper wound care guidance, and appropriate post-procedure monitoring. Administration site risks: Intra-articular injection carries a small risk of post-procedure inflammatory flare (typically self-limiting over 24-48 hours) and very rare infection risk. Intravenous administration carries the standard risks of IV access. Processing-related risks: Although rare, any biological processing step introduces the theoretical possibility of contamination — ALIV's laboratory protocols include quality checks at multiple stages to minimise this risk. Inflammatory response: A small proportion of patients experience a temporary increase in inflammation in the first week after ACT as the paracrine signalling initiates the tissue response — this typically resolves spontaneously and is not a sign of adverse outcome. See the full protocol: what to expect on ACT procedure day.

Who Should Not Have ACT: Contraindications

Absolute contraindications to ACT at ALIV include: active malignancy (cancer) — growth factor administration in the context of active cancer carries theoretical tumour stimulation risk; active systemic infection; severe coagulopathy (bleeding disorder) that makes harvest procedures unsafe; and conditions that make anaesthesia for the harvest procedure unsafe. Relative contraindications are assessed individually at the pre-ACT consultation: significant immunosuppressive medication use, severe systemic disease with limited life expectancy, and advanced organ failure where the regenerative capacity of the tissue is too compromised to respond meaningfully.

Can ACT be done if I am on blood thinners?

Anticoagulant and antiplatelet medications (warfarin, aspirin, clopidogrel, newer direct oral anticoagulants) need to be assessed at the pre-ACT consultation. Depending on the medication, the indication for its use, and the specific harvest procedure planned, a temporary cessation period may be appropriate — managed in coordination with the prescribing cardiologist or physician. Patients should not stop blood thinners without explicit physician guidance; this is a collaborative clinical decision, not a unilateral one.

Is ACT safe for elderly patients?

Age alone is not a contraindication to ACT. Many of ALIV's patients receiving ACT for conditions like osteoarthritis, Parkinson's, and restorative anti-ageing are in their 60s, 70s, and older. The relevant safety considerations for older patients are not age per se but frailty, coexisting medical conditions, and medications — all of which are assessed at the pre-ACT consultation. The harvest procedure under local anaesthesia is generally well-tolerated even in older adults with appropriate pre-procedure assessment.

Has anyone had a serious adverse event from ACT at ALIV?

ALIV maintains an active clinical safety monitoring programme and documents outcomes across its ACT patient cohort. Serious adverse events from ACT procedures have been rare. The most common adverse experiences are mild and temporary: procedural site discomfort, post-procedure inflammatory flare, and temporary fatigue in the first one to two weeks after the procedure. Patients are provided with a clear post-procedure support contact and monitoring protocol to ensure any unexpected responses are identified and managed promptly.